DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Delta Hotels Ottawa City Centre

2022年10月18日 (火) 午後 1:00 - 2022年10月19日 (水) 午後 9:10

101 Lyon Street North, Ottawa, ON K1R 5T9, Canada

Canada Annual Meeting

Session 7, Tracks B, C: Key Considerations for Successful Risk Minimization

Session Chair(s)

Marilyne  Chamoun, MSc

Marilyne Chamoun, MSc

Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau

Health Canada, Canada

Myriam  Salem, MSc

Myriam Salem, MSc

Pharmacovigilance Manager

Health Canada, Canada

The success of a risk minimization measure or program relies on successful design and implementation of the measures and having good strategies in place to evaluate its effectiveness and overall impact. In this session, we will look more closely at the impact that risk minimization measures can have on stakeholders and discuss design considerations and strategies to ensure successful integration into the target healthcare system.

Learning Objective :
  • Discuss important considerations for the design and implementation of risk minimization measures that are fit-for-purpose and adaptable to the local healthcare system
  • Explain the importance of assessing the effectiveness and impact of risk minimization measure on stakeholders
  • Identify data sources and innovative research methods that can generate information on different aspects of risk minimization measure implementation and impact

Speaker(s)

Yola  Moride, PhD, FISPE

Methodological Considerations for Successful Risk Minimization

Yola Moride, PhD, FISPE

YolaRX Consultants, Canada

President

Sarah  Frise, PhD, MS

Key Considerations for Successful Risk Minimisation

Sarah Frise, PhD, MS

AstraZeneca, Canada

Global Head Safety Epidemiology and Risk Management

Marilyne  Chamoun, MSc

Speaker

Marilyne Chamoun, MSc

Health Canada, Canada

Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。